Dashboard
Manage Tickers

AZNASTRAZENECA PLC

Nasdaq astrazeneca.com


$ 77.93 $ -0.05 (-0.06 %)    

Monday, 01-Jul-2024 15:59:59 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 481.74 $ 1.45 (0.3 %)
DIA $ 391.56 $ 0.43 (0.11 %)
SPY $ 545.33 $ 1.11 (0.2 %)
TLT $ 90.13 $ -1.65 (-1.8 %)
GLD $ 215.59 $ 0.58 (0.27 %)
$ 77.94
$ 77.69
$ 0.00 x 0
$ 0.00 x 0
$ 77.64 - $ 78.69
$ 59.55 - $ 80.86
2,568,596
na
121.74B
$ 0.55
$ 7.12
TBD
na
na ($ 0.02)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

astrazenecas-covid-19-prevention-drug-for-patients-with-weak-immune-systems---european-medicines-agency-accepts-marketing-application-under-accelerated-assessment
AstraZeneca's COVID-19 Prevention Drug For...
07/01/2024 16:43:08

The European Medicines Agency has accepted AstraZeneca's marketing authorization application for sipavibart, an investigati...

astrazenecas-imfinzi-durvalumab-and-lynparza-olaparib-have-been-recommended-for-approval-in-the-european-union-as-treatment-for-certain-patients-with-primary-advanced-or-recurrent-endometrial-cancer
AstraZeneca's Imfinzi (Durvalumab) And Lyn...
07/01/2024 10:04:13

Imfinzi plus chemotherapy as 1st-line treatment followed by Lynparza and Imfinzi has been recommended for patients with misma...

astrazenecas-marketing-authorization-application-for-sipavibart-has-been-accepted-under-an-accelerated-assessment-procedure-by-the-european-medicines-agency-for-the-pre-exposure-prophylaxis-prevention-of-covid-19-in-immunocompromised-patients
AstraZeneca's Marketing Authorization Appl...
07/01/2024 09:49:26

china-approves-astrazenecas-tagrisso-chemotherapy-combo-regime-for-previously-untreated-lung-cancer-patients
China Approves AstraZeneca's Tagrisso-Chem...
06/26/2024 14:08:24

China has approved AstraZeneca's Tagrisso (osimertinib) combined with pemetrexed and platinum-based chemotherapy for first-...

china-approves-astrazenecas-tagrisso-osimertinib-with-the-addition-of-pemetrexed-and-platinum-based-chemotherapy-for-the-first-line-treatment-of-locally-advanced-or-metastatic-egfr-mutated-non-small-cell-lung-cancer
China Approves AstraZeneca's Tagrisso (Osi...
06/26/2024 08:56:41

astrazenecas-blockbuster-cancer-drug-imfinzi-flunks-as-follow-up-in-type-of-early-stage-lung-cancer-but-hits-primary-goal-in-phase-3-bladder-cancer-study
AstraZeneca's Blockbuster Cancer Drug Imfi...
06/25/2024 13:45:05

AstraZeneca's ADJUVANT BR.31 Phase 3 trial reveals Imfinzi didn't meet the primary endpoint for disease-free survival i...

japan-approves-astrazenecas-tagrisso-osimertinib-with-addition-of-pemetrexed-and-platinum-based-chemotherapy-as-new-first-line-treatment-for-patients-with-egfr-mutated-advanced-non-small-cell-lung-cancer
Japan Approves AstraZeneca's Tagrisso (Osi...
06/25/2024 09:04:56

astrazenecas-high-level-results-from-adjuvant-br31-phase-3-trial-of-imfinzi-did-not-achieve-statistical-significance-for-primary-endpoint-of-disease-free-survival-versus-placebo-in-early-stage-non-small-cell-lung-cancer
AstraZeneca's High-level Results From ADJU...
06/25/2024 09:02:36

astrazenecas-niagara-phase-3-trial-of-imfinzi-durvalumab-plus-chemotherapy-showed-statistically-significant-and-clinically-meaningful-improvement-in-event-free-survival-and-overall-survival-vs-neoadjuvant-chemotherapy-in-muscle-invasive-bladder-cancer
AstraZeneca's NIAGARA Phase 3 Trial Of Imf...
06/25/2024 08:59:42

supreme-court-backs-pharmaceutical-giants-in-iraq-terrorism-funding-case
Supreme Court Backs Pharmaceutical Giants ...
06/24/2024 19:47:37

The U.S. Supreme Court supports pharmaceutical companies, led by AstraZeneca, in a lawsuit accusing them of funding terrorism i...

gilead-sciences-faces-wall-street-speculation-about-obesity-drugs-despite-focus-on-liver-treatments
Gilead Sciences Faces Wall Street Speculat...
06/21/2024 15:42:22

Gilead Sciences faces Wall Street speculation about its potential in the obesity drug market despite its focus on liver treatme...

covid-19-pharma-stars-continue-their-quest-to-set-new-standards-in-cancer-treatment
Covid-19 Pharma Stars Continue Their Quest...
06/18/2024 14:19:12

AstraZeneca PLC (NASDAQ: AZN) kicked off the week by receiving approval from the U.S. Food and Drug Administration for its bloc...

astrazenecas-combination-cancer-drug-for-advanced-breast-cancer-study-flunks-late-stage-trial
AstraZeneca's Combination Cancer Drug For ...
06/18/2024 13:22:47

AstraZeneca announced that the CAPItello-290 Phase 3 trial for Truqap (capivasertib) combined with paclitaxel in advanced or me...

astrazenecas-capitello-phase-3-trial-for-truqap-capivasertib-combined-with-paclitaxel-in-locally-advancedmetastatic-triple-negative-breast-cancer-did-not-meet-the-dual-primary-endpoints-of-improvement-in-overall-survival-versus-paclitaxel-plus-placebo
AstraZeneca's CAPItello Phase 3 Trial For ...
06/18/2024 08:53:13

whats-going-on-with-small-cap-cancer-focused-nurix-therapeutics-on-monday
What's Going On With Small-Cap Cancer Focu...
06/17/2024 15:47:08

Nurix Therapeutics presented updated clinical data for NX-5948, an orally bioavailable BTK degrader, at the EHA Congress. NX-59...

fda-approves-astrazeneca-treatment-for-advanced-endometrial-cancer
FDA Approves AstraZeneca Treatment For Adv...
06/17/2024 10:38:41

AstraZeneca's breakthrough drug, Imfinzi, combined with chemotherapy, has been officially approved by the FDA to treat adva...

astrazeneca-says-calquencechemo-combo-data-shows-additional-168-months-without-disease-progression-in-patients-with-certain-type-of-blood-cancer
AstraZeneca Says Calquence/Chemo Combo Dat...
06/17/2024 09:32:48

AstraZeneca shares data from the ECHO Phase 3 trial on Calquence plus bendamustine and rituximab in untreated mantle cell lymph...

reports-sunday-astrazeneca-reports-27-decrease-in-progression-or-death-risk-with-calquence-combination-in-phase-iii-mantle-cell-lymphoma-study
Reports Sunday, AstraZeneca Reports 27% De...
06/17/2024 07:21:26

First and only BTK inhibitor to demonstrate favorable overall survival trend vs. standard-of-care chemoimmunotherapy in this se...

astrazeneca-reports-fda-approved-durvalumab-with-chemotherapy-for-mismatch-repair-deficient-primary-advanced-or-recurrent-endometrial-cancer
AstraZeneca Reports FDA Approved Durvaluma...
06/14/2024 20:13:39

-Reuters

Core News & Articles
FDA On June 13 Updates Advice To Manufactu...
06/14/2024 18:13:02

- Reuters

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

07/01/2024 Globe Life Inc. f/k/a Torchmark Corporation (GL)
07/01/2024 Equinix, Inc. (EQIX)
07/02/2024 Intel Corporation (INTC)
07/05/2024 AXT, Inc. (AXTI)
07/05/2024 Altimmune, Inc. (ALT)
07/09/2024 Li Auto Inc. (LI)
07/12/2024 Inari Medical, Inc. (NARI)
07/12/2024 Sprout Social, Inc. (SPT)
07/15/2024 UnitedHealth Group Inc. (UNH)
07/16/2024 Teladoc Health, Inc. (TDOC)

NEW CASE INVESTIGATION

Ooma Inc (OOMA) AnaptysBio Inc (ANAB)